Importing medicines into Iraq is a tightly regulated activity that combines pharmaceutical law, customs law, and commercial licensing. No company regardless of size or international reputation may bring pharmaceutical products into Iraqi territory without first obtaining the necessary import authorizations from the Ministry of Health, and, where applicable, the General Company for Marketing of Drugs and Medical Appliances (KIMADIA). What makes the system distinctive is its two-tier structure: the product itself must be registered, and the importer must hold a valid import licence covering each specific consignment. Both layers must be in place for the goods to clear customs lawfully.
The legal framework rests on the Public Health Law No. 89 of 1981, the Drug Control Law and its implementing instructions, customs legislation, and ministerial orders issued by the Ministry of Health. These instruments work together, and a gap or inconsistency in any one of them — for example, a registered product imported by an unlicensed party, or a licensed importer bringing in an unregistered product is enough to render the importation unlawful.
Who May Import?
Only specific categories of entities are permitted to import pharmaceuticals into Iraq. The principal authorized importers are licensed scientific offices acting on behalf of foreign manufacturers, KIMADIA for public sector procurement, and registered drugstores (pharmaceutical wholesalers) that hold the appropriate import endorsement. Certain hospitals and medical institutions may also import for direct use under special authorization, typically for specialty products or compassionate-use scenarios. Individual pharmacies, retail outlets, and unrelated commercial companies cannot import medicines and any attempt to do so exposes those involved to confiscation of the goods, criminal penalties under the Public Health Law, and revocation of related licenses.
Scientific offices are the most common vehicle through which foreign pharmaceutical companies access the Iraqi market. To be licensed, the scientific office must have a qualified Iraqi pharmacist as responsible technical director, appropriate premises that pass Ministry inspection, financial guarantees, and a clear power of attorney from the foreign principal manufacturer. The scientific office is legally responsible for the products it imports and represents, and that responsibility extends to quality, safety, and labeling issues that may arise long after the goods have cleared customs.
Consignment-Level Import Permit
Holding a general importer license is not enough; for every actual shipment, the licensed importer must obtain a specific import permit from the IDCD. This consignment-level permit identifies the product (which must already be registered), the manufacturer, the quantity, the batch numbers and expiry dates, the country of origin, the intended port of entry, and the consignee. The application is supported by the proforma invoice, the product registration certificate, the batch certificate of analysis, the GMP certificate for the manufacturing site, and where applicable certificates of free sale and pharmaceutical product.
One detail that catches many importers unprepared is the shelf-life rule. Iraq generally requires that imported pharmaceuticals have no less than two-thirds of their total approved shelf life remaining at the time of arrival at the port of entry. Consignments that arrive with less remaining shelf life may be refused at the border, returned to the country of origin, or destroyed at the importer’s expense. This rule has commercial consequences that should be planned for in production scheduling, freight arrangements, and inventory management at the manufacturer’s end.
Special Categories
Some categories of products require additional approvals beyond the standard import procedure. Narcotics and other controlled substances require special permits issued under the Narcotics Law and are subject to United Nations Single Convention obligations. Biologics and vaccines often require additional batch release certificates and may be subject to lot-by-lot testing through the National Quality Control Laboratory. Cold chain products carry additional documentation and temperature monitoring requirements throughout shipping and inspection. Each of these categories has its own rhythm, and bundling them with general shipments rarely works in practice.
Customs Clearance
Upon arrival at the port of entry, the consignment is subject to inspection by Ministry of Health inspectors, who verify documents, examine the physical condition of the goods, check labels and Arabic inserts where required, and may draw samples for laboratory analysis. The consignment remains under customs supervision until clearance is granted. Importers should plan their logistics with appropriate margins to absorb documentary discrepancies, sampling delays, and inspection backlogs particularly at busy periods when consignments queue up for review.
Public Sector Imports through KIMADIA
Public sector procurement is dominated by KIMADIA, which conducts tenders for medicines required by Ministry of Health hospitals and primary care facilities. Foreign manufacturers wishing to supply KIMADIA generally do so through a local agent and must comply with specific KIMADIA registration and prequalification requirements, including regulatory files, samples, and pricing in accordance with tender specifications. KIMADIA participation is a substantial commercial commitment in its own right.
Ongoing Obligations
Once the goods have cleared customs, the importer’s obligations continue. Traceability and record-keeping requirements typically run for at least five years and must permit the importer to identify, on demand, the full chain of custody from the manufacturer to the eventual recipient. Pharmacovigilance reporting begins as soon as the product enters the market. Any quality defects, recalls, or safety signals must be promptly notified by the Ministry of Health, and the importer must cooperate fully with periodic inspections. These obligations are not merely administrative — they form the basis on which the Ministry assesses whether the importer remains fit to hold its license.
Consequences of Non-Compliance
Non-compliance with the import regime carries serious consequences. Administrative fines are routine; suspension or revocation of the import licence is common in more significant cases; criminal prosecution under the Public Health Law is available for serious or deliberate breaches; and personal liability can attach to the technical director and managers responsible. The most frequent violations we see involve importation of unregistered products, falsified documentation, smuggling, and failure to maintain proper traceability records, each of which has caused even well-established companies to lose market access in Iraq.
How We Can Help
Etihad Law Firm advises importers, scientific offices, and foreign manufacturers on the entire spectrum of pharmaceutical import compliance in Iraq. We treat import licensing not as a one-off formality but as a structured legal compliance program, helping clients navigate evolving documentation standards, electronic submission requirements, and inspection protocols and representing them when difficulties arise at the border or before the Ministry.